Neoadjuvant immunotherapy for dMMR/MSI-H locally advanced rectal cancer patients: demystifying the 100% clinical complete response paradigm
Year: 2025
Type: article
Study design: Case Report
Abstract: Six months of treatment with dostarlimab followed by nonoperative management in case of clinical complete response (cCR) is the new standard-of-care for patients with microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) locally advanced rectal cancer (LARC). The most recent update of the seminal phase II trial by Cercek et al. shows a cCR rate of 100% that allowed sparing chemoradiation and surgery to all included patients. Here, we present three clinical cases of patients with dMMR and MSI-H LARC treated with neoadjuvant dostarlimab at three Italian institutions with radiological evidence of disease progression while on treatment and discuss potential similarities among them to understand when and how this apparently rare event may occur.
Source: The Oncologist
Institutions: University of Pisa, Azienda Ospedaliera Universitaria Pisana, Fondazione IRCCS Istituto Nazionale dei Tumori, University of Campania "Luigi Vanvitelli", Inserm, Université Paris Cité, Sorbonne Université, Centre de Recherche des Cordeliers, Ospedale Policlinico San Martino, Assistance Publique – Hôpitaux de Paris, Hôpital Européen Georges-Pompidou
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,852
Funders: European Commission, Università di Pisa
Award: G1033601615
OpenAlex ID: W4416888751